Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
ACS Infect Dis ; 10(7): 2419-2442, 2024 Jul 12.
Article in English | MEDLINE | ID: mdl-38862127

ABSTRACT

ELQ-300 is a potent antimalarial drug with activity against blood, liver, and vector stages of the disease. A prodrug, ELQ-331, exhibits reduced crystallinity and improved in vivo efficacy in preclinical testing, and currently, it is in the developmental pipeline for once-a-week dosing for oral prophylaxis against malaria. Because of the high cost of developing a new drug for human use and the high risk of drug failure, it is prudent to have a back-up plan in place. Here we describe ELQ-596, a member of a new subseries of 3-biaryl-ELQs, with enhanced potency in vitro against multidrug-resistant Plasmodium falciparum parasites. ELQ-598, a prodrug of ELQ-596 with diminished crystallinity, is more effective vs murine malaria than its progenitor ELQ-331 by 4- to 10-fold, suggesting that correspondingly lower doses could be used to protect and cure humans of malaria. With a longer bloodstream half-life in mice compared to its progenitor, ELQ-596 highlights a novel series of next-generation ELQs with the potential for once-monthly dosing for protection against malaria infection. Advances in the preparation of 3-biaryl-ELQs are presented along with preliminary results from experiments to explore key structure-activity relationships for drug potency, selectivity, pharmacokinetics, and safety.


Subject(s)
Antimalarials , Plasmodium falciparum , Quinolones , Antimalarials/pharmacology , Antimalarials/chemistry , Antimalarials/pharmacokinetics , Animals , Plasmodium falciparum/drug effects , Mice , Quinolones/pharmacology , Quinolones/chemistry , Quinolones/pharmacokinetics , Malaria/drug therapy , Malaria/prevention & control , Humans , Prodrugs/pharmacology , Prodrugs/chemistry , Prodrugs/pharmacokinetics , Malaria, Falciparum/drug therapy , Malaria, Falciparum/prevention & control , Female , Structure-Activity Relationship
2.
Future Med Chem ; 14(22): 1611-1620, 2022 11.
Article in English | MEDLINE | ID: mdl-36349868

ABSTRACT

Background: In 1948, the synthesis and Plasmodium lophurae activity of 2-hydroxy-1,4-naphthoquinones containing 3-alkyldiarylether side chains was reported. Method/results: The synthesis of five related compounds, designed to be more metabolically stable, was pursued. The compounds were synthesized using a radical alkylation reaction with naphthoquinones. One compound had a lower IC50 value against various strains of Plasmodium falciparum and assay data indicate that it binds to the Qo site of cytochrome bc1. With a low yield for the radical alkylation of the most active compound, a reductive alkylation method with used to improve reaction yields. Conclusion: Further synthetic knowledge was obtained, and the assay data indicate that there are sensitivity differences between avian and human malarial parasites for these molecules.


Malaria is a disease caused by a parasite that affects millions of people each year and results in many deaths. In 1948, 300 structurally related compounds were made and tested for antimalarial activity with the goal of finding a drug to treat the disease. From this work, promising compounds were identified and this work has served as a starting point for further investigations. Based on recent discoveries, this study made variations of promising 1948 compounds to investigate whether antimalarial activity could be improved. These compounds were made using two different methods. One derivative was found to be more potent than the original compound but was not the one expected based on the 1948 work.


Subject(s)
Antimalarials , Naphthoquinones , Humans , Plasmodium falciparum , Antimalarials/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...